Novartis AG (NVSEF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
As of 03:12PM EST. Market open.
| Previous Close | 78.90 |
| Open | 78.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 78.90 - 78.90 |
| 52 Week Range | 78.78 - 97.30 |
| Volume | |
| Avg. Volume | 25,116 |
| Market Cap | 177.871B |
| Beta (5Y Monthly) | 0.52 |
| PE Ratio (TTM) | 22.67 |
| EPS (TTM) | 3.48 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.22 (3.47%) |
| Ex-Dividend Date | Mar. 04, 2021 |
| 1y Target Est | N/A |
- Zacks
Novartis (NVS) Highlights Growth Profile at its R&D Day
Novartis (NVS) throws light on its pipeline progress, key areas of focus and long-term targets at its R&D day. Here, we discuss key highlights from the same.
- Zacks
Aurinia (AUPH) Stock Up on Potential Acquisition Rumors
Aurinia (AUPH) gains on rumors of a potential acquisition yet again. Reportedly, the company is being eyed by Novartis.
- Motley Fool
Why Aurinia Pharmaceuticals Stock Bolted Higher Today
Shares of the autoimmune disease specialist Aurinia Pharmaceuticals (NASDAQ: AUPH) are up by a noteworthy 15.5% as of 1:10 p.m. ET Thursday afternoon. Rumors began to swirl about a possible buyout this morning after Novartis (NYSE: NVS) reportedly said during its research and development day that it will focus on smaller bolt-on acquisitions, instead of megadeals. Aurinia has repeatedly been the topic of the buyout rumor mill in 2021.
